West Virginia bans 7 artificial food dyes, citing health concerns
West Virginia has outlawed foods that contain some artificial dyes or other additives, in one of the most comprehensive statewide bans of its kind. The move cites potentially harmful health effects and comes amid a broader push from scientists and government leaders to clamp down on synthetics in the nation's food supply.
On Monday, West Virginia Gov. Patrick Morrisey signed into law a bill that was passed earlier by legislators to eliminate seven artificial dyes — Red Dye No. 3, Red Dye No. 40, Yellow Dye No. 5, Yellow Dye No. 6, Blue Dye No. 1, Blue Dye No. 2 and Green Dye No. 3 — from food products and drugs sold in the state. The preservatives butylated hydroxyanisole and propylparaben will also be banned.
The dyes will not be allowed in meals served as part of school nutrition programs starting on Aug. 1 this year, while the dyes and the two preservatives will not be permitted in drugs and food sold in the state starting on Jan. 1, 2028, according to the governor's office.
"West Virginia ranks at the bottom of many public health metrics, which is why there's no better place to lead the Make America Healthy Again mission," Morrisey said in a statement, citing the campaign slogan popularized by Health and Human Services Secretary Robert F. Kennedy Jr., who has said he is prioritizing the removal of artificial dyes from food and drinks sold around the United States. "By eliminating harmful chemicals from our food, we're taking steps toward improving the health of our residents and protecting our children from significant long-term health and learning challenges."
The latest ban in West Virginia follows a pair of laws passed in California in recent years to remove some additives from foods sold statewide and synthetic dyes from school meals. Dozens of other U.S. states have introduced legislation to ban or more strictly regulate certain food additives, including artificial dyes, since the beginning of the year, according to the Environmental Working Group, an advocacy organization focused on food safety.
Thirty-six color additives are approved by the Federal Drug Administration for use in food and drinks in the U.S., including nine artificial dyes.
Rising concerns from advocacy groups and scientists about possible health consequences of synthetic food components, particularly for children, prompted the FDA to undertake a new effort in December to review previously approved additives, although the agency's deputy commissioner for human foods warned at the time that budget restrictions might prevent a timely turnaround. In January, the FDA announced its decision to revoke the authorization for one dye, Red 3, to be added to foods, after evidence showed a link between the dye and cancer in laboratory animals.
Sen. Rand Paul says he thinks Supreme Court will uphold the Alien Enemies Act for deportations
George Clooney: The 2025 60 Minutes Interview
Denzel Washington and Jake Gyllenhaal on their Broadway "Othello"
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Breakthrough procedure helps prevent amputations for Sacramento area patients
( — A breakthrough surgery helping save limbs and lives took place in Sacramento on Wednesday morning. The procedure aims to treat people suffering from Peripheral Artery Disease. PAD is a serious and rarely-treated circulatory condition that restricts blood flow to the limbs due to narrowed blood vessels. It kills more people than breast, colon, and prostate cancer combined. 'Plaque that builds up in these arteries causes not only hardening of the arteries but also plaque in these blood vessels,' said Dr. Inder Singh, an interventional cardiovascular specialist at TLC Vascular. When blood can't flow properly, minor wounds can become dangerous. They can lead to infection and, in some cases, amputation. Michaels Distributing Center in San Joaquin County set to close, affecting over 200 jobs 'If they get an injury or they get a wound or they get a scratch, those will not heal because they don't have enough, adequate perfusion to heal those wounds,' Dr. Singh said. Helping to change patient outcomes, Dr. Singh is now performing a first-of-its-kind procedure using a newly FDA-cleared removable stent called SPUR. 'The idea with it is that basically that kind of treatment that deep penetrates into the tissue and treats it, it will prevent future closure or at least prolong the time from when the blood vessels close,' said Dr. Singh. 'Enabling the patients to be able to heal their wounds, which is really the main outcome we're looking for.' is the first in the Sacramento area to use SPUR, designed specifically for the small, fragile arteries below the knee. Unlike a traditional stent, the spur temporarily holds the vessel open and then is removed, leaving nothing behind. Charges filed against former Cal Fire employee in child pornography case 'We can see somebody on an outpatient basis one day and actually fix a problem rather than put a band-aid on, you know, the incorrect problem,' said Shelby Adney, a nurse practitioner at TLC Vascular. It's an innovative procedure now preventing amputations, healing wounds, and maintaining patients' normal lives. 'Once you can preserve that and heal their wounds… they get their life back,' Dr. Singh said. 'They're ambulatory. They can spend time with their family. You can do a lot of things that most people expect to do.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
4 hours ago
- Yahoo
Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD
NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on continued momentum with United States Food and Drug Administration (FDA) regarding both accelerated approval pathway for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic chronic heart failure with reduced ejection fraction (HFrEF) and inflammation, and label extension for Ryoncil® (remestemcel-L-rknd) in adults with steroid refractory acute graft versus host disease (SR-aGvHD). In the first week of June, Mesoblast held a Type B meeting with FDA under its Regenerative Medicines Advanced Therapy (RMAT) designation for REVASCOR to discuss components of a potential filing for a Biologics License Application (BLA). There was general alignment on items regarding chemistry, manufacturing & controls (CMC), potency assays for commercial product release, and proposed design and primary endpoint for the confirmatory trial post-approval. The Company will await the final minutes from FDA in order to provide detailed feedback and timelines for potential filing. In early July, Mesoblast has an upcoming meeting with FDA to discuss a pivotal trial of Ryoncil® in adults with SR-aGvHD. This trial will be conducted with the NIH-funded Bone Marrow Transplant Clinical Trials Network (BMT-CTN), the objective being to extend the product's label from children to adults with SR-aGvHD. Ryoncil® is the first and only mesenchymal stromal cell product approved by the FDA for any indication. Ryoncil® became commercially available for purchase in the United States on March 28, 2025, within one quarter of receiving FDA approval to treat children with SR-aGvHD. More than 20 transplant centers will have been onboarded by the end of the quarter, exceeding the company's expectations at product launch. Mesoblast has continued to expand coverage for Ryoncil® to over 220 million US lives insured by commercial and government payers. To date, 37 of the 51 States provide fee-for-service Medicaid coverage for Ryoncil® through Orphan Drug Lists or medical exception / prior authorization (PA) process. The remainder will come online July 1, 2025, with mandatory coverage for all 24 million lives. 'We are very pleased with the momentum of interactions with FDA on both our cardiac and GvHD programs,' said Mesoblast Chief Executive Dr. Silviu Itescu. 'We are also encouraged by the strength of the of the Ryoncil® commercial launch, the rate of hospital onboarding, physician adoption, and payor coverage exceeding our expectations in the ten weeks since commercial launch. We will be providing an update on sales of Ryoncil® in our quarterly activities report at the end of next month.' About Mesoblast Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company's proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process. Mesoblast's RYONCIL® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. RYONCIL is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China. About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications are expected to provide commercial protection extending through to at least 2041 in major markets. About Mesoblast manufacturing: The Company's proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see LinkedIn: Mesoblast Limited and X: @Mesoblast Forward-Looking StatementsThis press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast's preclinical and clinical studies, and Mesoblast's research and development programs; Mesoblast's ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast's ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast's RYONCIL for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast's product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast's ability to enter into and maintain established strategic collaborations; Mesoblast's ability to establish and maintain intellectual property on its product candidates and Mesoblast's ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast's expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast's financial performance; developments relating to Mesoblast's competitors and industry; and the pricing and reimbursement of Mesoblast's product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast's actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise. Release authorized by the Chief Executive. For more information, please contact:Paul Hughes T: +61 3 9639 6036 Allison Worldwide Emma Neal T: +1 603 545 4843 E: BlueDot Media Steve Dabkowski T: +61 419 880 486 E: steve@
Yahoo
5 hours ago
- Yahoo
2 items added to ‘Dirty Dozen' list of most pesticide-contaminated produce
The Environmental Working Group (EWG) added blackberries and potatoes to its 'Dirty Dozen' list of produce containing the most residue of potentially harmful pesticides. Blackberries and potatoes landed in spots No. 10 and No. 12, respectively, on the updated list released Wednesday. They were added based on new data from the U.S. Department of Agriculture (USDA), which tested blackberries for the first time in 2023. The USDA data found that 93 percent of blackberry samples had pesticide residues, with an average of four different pesticides per sample. More than half of blackberry samples contained residue of the pesticide cypermethrin — which the Environmental Protection Agency (EPA) classifies as a possible human carcinogen. Potatoes landed on the list after USDA released new data showing 90 percent of samples contained chlorpropham, a chemical banned in the European Union because of health concerns. The legacy produce still topped the 'Dirty Dozen' list. Spinach ranked No. 1, with more pesticide residue by weight than any other type of produce, and strawberries followed at No. 2. 'Kale, Collard, and Mustard Greens' collectively placed No. 3 — and EWG noted that more than half of kale samples were 'tainted' by a 'possibly cancer-causing pesticide.' The 'Dirty Dozen' list ranked grapes as No. 4, peaches as No. 5, cherries as No. 6, nectarines as No. 7, pears as No. 8, apples as No. 9, blackberries as No. 10, blueberries as No. 11 and potatoes as No. 12. The guide analyzed pesticide residue data from USDA tests of more than 53,000 samples of 47 fruits and vegetables, EWG said in a press release. The tests are conducted after the produce samples are washed, scrubbed or peeled, 'as is typical for each type of produce.' EWG said the pesticide residue remained on the produce, but washing fruits and vegetables 'remains an important step to reduce pesticide levels, dirt, and possible bacterial contamination.' EWG encourages consumers to buy organic produce if they do not want to avoid the 'Dirty Dozen' produce items. EWG also publishes a 'Clean Fifteen' list of produce with overall lower levels of toxicity. Pineapples led that list this year, followed by sweet corn (fresh and frozen), avocados, papayas and onion as the top five produce items. Nos. 6-15 included sweet peas (frozen), asparagus, cabbage, watermelon, cauliflower, bananas, mangoes, carrots, mushrooms, and kiwi. EWG said nearly 60 percent of conventionally grown produce on the 'Clean Fifteen' list had 'no detectable pesticide residues,' while more than 9 in 10 samples of produce on the 'Dirty Dozen' list contained residues of potentially harmful pesticides. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
